Zacks Investment Research lowered shares of PLx Pharma Inc (NASDAQ:PLXP) from a buy rating to a sell rating in a report published on Tuesday.

According to Zacks, “PLx Pharma Inc. is a specialty pharmaceutical company. It focused on developing clinically validated and patent-protected PLxGuard(TM) delivery system to provide safe and effective aspirin products. PLx Pharma Inc., formerly known as Dipexium Pharmaceuticals Inc., is based in NEW YORK, United States. “

A number of other equities analysts have also weighed in on the company. Redburn Partners raised PLx Pharma to an outperform rating in a research report on Tuesday, August 1st. UBS AG raised PLx Pharma from a market perform rating to an outperform rating and set a $12.00 target price for the company in a research report on Monday, July 31st. One research analyst has rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company. The company has a consensus rating of Hold and an average price target of $9.63.

PLx Pharma (NASDAQ PLXP) opened at 6.3501 on Tuesday. PLx Pharma has a 52-week low of $5.60 and a 52-week high of $126.72. The company’s market cap is $55.17 million. The company’s 50-day moving average is $6.53 and its 200 day moving average is $7.55.

ILLEGAL ACTIVITY NOTICE: “PLx Pharma Inc (PLXP) Downgraded by Zacks Investment Research to Sell” was posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at

Several institutional investors have recently added to or reduced their stakes in PLXP. Heritage Way Advisors LLC bought a new stake in shares of PLx Pharma during the 2nd quarter valued at about $197,000. University of Texas Investment Managment Co. bought a new stake in shares of PLx Pharma during the 2nd quarter valued at about $385,000. Finally, Susquehanna International Group LLP bought a new stake in shares of PLx Pharma during the 2nd quarter valued at about $1,413,000. Institutional investors and hedge funds own 19.68% of the company’s stock.

PLx Pharma Company Profile

PLx Pharma Inc, formerly Dipexium Pharmaceuticals, Inc, is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company’s products and technology includes PLxGuard delivery system, Aspertec 325 mg, PL1100/PL1200 Ibuprofen.

Get a free copy of the Zacks research report on PLx Pharma (PLXP)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for PLx Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PLx Pharma Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.